wire - news in brief


Category


Years
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008

Last News


Results 151 - 200 of 285.

Life Sciences
19.10.2016
Overcoming egocentricity increases self-control
In the study, people chose between a payoff that only benefitted themselves and a payoff that benefitted them less but also benefitted another person. (Image: iStock.com/eljule). Should I buy a new car now or save the money for retirement? Such situations require self-control in order to resist the immediately tempting offer for the sake of more important outcomes in the future.
Medicine/Pharmacology
18.10.2016
Soil-Transmitted Helminthiasis Advisory Committee Convenes at Swiss TPH
Soil-Transmitted Helminthiasis Advisory Committee convenes at Swiss TPH This year's annual meeting of the Soil-Transmitted Helminthiasis Advisory Committee, chaired by Jürg Utzinger, is hosted at Swiss TPH.
Medicine/Pharmacology
18.10.2016
Alcon launches the CyPass Micro-Stent at the American Academy of Ophthalmology (AAO) 2016 annual meeting
Alcon to host first live training program on the use of the CyPass Micro-Stent, a minimally invasive glaucoma surgical device to treat cataract patients with mild to moderate primary open-angle glauc
Medicine/Pharmacology - Physics/Materials Science
17.10.2016
Peptides vs. superbugs
Peptides vs. superbugs
Several peptides have an antibacterial effect - but they are broken down in the human body too quickly to exert this effect.
Physics/Materials Science - Chemistry
17.10.2016
Nanowires as Sensors in New Type of Atomic Force Microscope
Nanowires as Sensors in New Type of Atomic Force Microscope
A new type of atomic force microscope (AFM) uses nanowires as tiny sensors. Unlike standard AFM, the device with a nanowire sensor enables measurements of both the size and direction of forces. Physicists at the University of Basel and at the EPF Lausanne have described these results in the recent. Nanowires are extremely tiny filamentary crystals which are built-up molecule by molecule from various materials and which are now being very actively studied by scientists all around the world because of their exceptional properties.
Mechanical Engineering/Mechanics
15.10.2016
From weighty silence to clamorous applause
From weighty silence to clamorous applause
The first ever Cybathlon took place a week ago in the sold-out Swiss Arena in Kloten. Founder Robert Riener takes stock.
Physics/Materials Science - Chemistry
13.10.2016
24 hours at the ESI Platform (video)
How can surplus power that can't be fed into the electric grid be made usable? A fictitious day at the Energy System Integration Platform at the Paul Scherrer Institute PSI.
Event - Computer Science/Telecom
13.10.2016
Careers/Employment - Psychology
12.10.2016
Swiss employees do not hold back on cynical behaviour
Swiss employees do not hold back on cynical behaviour
This year's Swiss Human Relations Barometer focuses on the topic “loyalty and cynicism” – specifically, the tension between how employees experience and demonstrate both loyalty and
Physics/Materials Science - Microtechnics/Electroengineering
11.10.2016
Selectively conductive or insulating
Selectively conductive or insulating
Highly sensitive X-ray scattering shows why an exotic material is sometimes a metal, sometimes an insulator. Some materials hold surprising – and possibly useful – properties: neodymium nickel oxide is either a metal or an insulator, depending on its temperature. This characteristic makes the material a potential candidate for transistors in modern electronic devices.
Medicine/Pharmacology - Social Sciences
10.10.2016
Reviewing the treatment of differences of sex development
Reviewing the treatment of differences of sex development
The SNSF is providing funding for University Children's Hospital Zurich's scientific review of the treatment of children with differences of sex development (DSD children). They used to be called hermaphrodites and intersexuals. From the 1950s onwards, it was customary for children and newborns with no clear biological gender to be assigned their "true" gender as soon as possible by exploiting pharmacotherapy or by surgically operating on them.
Physics/Materials Science - Event
10.10.2016
Molten salt reactors – exploring an alternative
Molten salt reactors – exploring an alternative
The Paul Scherrer Institute PSI was formed in 1988, in part from the Swiss Federal Institute for Reactor Research.
Medicine/Pharmacology - Life Sciences
09.10.2016
Novartis ALK+ metastatic NSCLC therapy Zykadia extends progression-free survival beyond 18 months in Phase II study
Progression-free survival (PFS) in ALKi-naïve patients is consistent with results previously reported from Phase I ASCEND-1 study Phase II study also showed overall response rate of 63.3% in ALKi
Medicine/Pharmacology - Life Sciences
08.10.2016
Novartis breakthrough therapy LEE011 plus letrozole demonstrates superior progression-free survival as first-line treatment for HR+/HER2- advanced breast cancer compared to a standard of care
Novartis breakthrough therapy LEE011 plus letrozole demonstrates superior progression-free survival as first-line treatment for HR+/HER2- advanced breast cancer compared to a standard of care LEE011 (ribociclib) plus letrozole reduced the risk of progression or death by 44% over letrozole alone, significantly extending progression-free survival (PFS) across all patient subgroups   Results showed that the combination significantly improved tumor
Medicine/Pharmacology - Administration/Government
08.10.2016
Novartis’ Tafinlar (dabrafenib) + Mekinist (trametinib) demonstrate superior overall survival benefit in advanced melanoma patients at three-year follow up
Novartis' Tafinlar (dabrafenib) + Mekinist (trametinib) demonstrate superior overall survival benefit in advanced melanoma patients at three-year follow up Latest data confirm an estimated 45% of pat
Computer Science/Telecom - Medicine/Pharmacology
07.10.2016
All systems go for the Cybathlon
More than 70 teams from 25 countries will compete in the Cybathlon tomorrow, Saturday 8 October. The competitors are gradually arriving in Zurich, armed with high-tech gadgets and full of energy and excitement.
Medicine/Pharmacology
07.10.2016
Zurich aims to extend high profile research on skin
Zurich aims to extend high profile research on skin
A new interdisciplinary, large-scale project from the "Hochschulmedizin Zürich" network focuses on skin research in Zurich.
Physics/Materials Science - Chemistry
06.10.2016
Physics/Materials Science - Chemistry
06.10.2016
Rapidly fueled for a long range journey
Rapidly fueled for a long range journey
Empa has launched Switzerland's first hydrogen station for passenger cars on its campus in Dübendorf.
Business/Economics - Architecture
06.10.2016
Physics/Materials Science - Chemistry
06.10.2016
Empa involved in Nobel research
Empa involved in Nobel research
Empa is delighted to acknowledge the awarding of the Nobel Prize in Chemistry 2016 to Bernard L. Feringa, Fraser Stoddart and Jean-Pierre Sauvage - as it made a major contribution in 2011 to a research project carried out by Bernard L. Feringa.
Physics/Materials Science - Chemistry
06.10.2016
Physics/Materials Science
06.10.2016
Technology gets disabled people back on their feet
Thanks to an exoskeleton developed at EPFL, people with paraplegia can stand up, walk and even climb steps.
Physics/Materials Science
05.10.2016
Physics/Materials Science
05.10.2016
Physicists at the PSI's large-scale research facilities are thinking beyond the Nobel Prize theories
Physicists at the PSI’s large-scale research facilities are thinking beyond the Nobel Prize theories
This year's Nobel Prize for Physics goes to David Thouless, Duncan Haldane, and Michael Kosterlitz for their investigations of topological phases and phase transitions in matter.
Medicine/Pharmacology - Life Sciences
05.10.2016
FDA grants breakthrough therapy designation for Roche’s Actemra/RoActemra in giant cell arteritis, a form of vasculitis
FDA grants breakthrough therapy designation for Roche's Actemra/RoActemra in giant cell arteritis, a form of vasculitis Roche recently announced positive results from a Phase III GCA clinical trial Fourteenth Breakthrough Therapy designation for Roche medicines There have been no therapies approved for GCA in more than 50 years Roche , announced today that the U.S.
Medicine/Pharmacology
04.10.2016
New chemical compound shows promising results against drug-resistant malaria parasites
The new chemical compound ACT-451840 is highly effective against most deadly malaria parasites in humans. It is also active against those parasites that have developed resistance against the standard therapies. The findings, published today in the journal PLOS Medicine, come from the Swiss Tropical and Public Health Institute (Swiss TPH) in collaboration with partners from industry and academia.
Medicine/Pharmacology - Computer Science/Telecom
04.10.2016
PlantVillage: A deep-learning app diagnoses crop diseases
PlantVillage: A deep-learning app diagnoses crop diseases
Scientists at EPFL and Penn State have trained a computer-learning algorithm to identify crop diseases with extremely high accuracy.
Physics/Materials Science - Administration/Government
04.10.2016
ERC funding of ?2.4 million for research on fundamental interactions in magnets
ERC funding of ?2.4 million for research on fundamental interactions in magnets
Christian Rüegg of the Paul Scherrer Institute PSI has been awarded a prestigious Consolidator Grant from the European Research Council (ERC).
Physics/Materials Science
04.10.2016
A
A "nano-golf course" to precisely assemble nanoparticles
The nanoparticles in the droplet encounter obstacles, they detach from the liquid and are captured by the holes©Valentin Flauraud/ 2016 EPFL 04.10.16 - EPFL researchers have developed a method to place and position hundreds of thousands of nanoparticles very precisely on a one centimeter square surface.
Life Sciences - Medicine/Pharmacology
04.10.2016
Developing brain regions in children hardest hit by sleep deprivation
Developing brain regions in children hardest hit by sleep deprivation
Sleep is vital for humans. If adults remain awake for longer than usual, the brain responds with an increased need for deep sleep. This is measured in the form of “slow wave activity” using electroencephalography (EEG). In adults, these deep-sleep waves are most pronounced in the prefrontal cortex – the brain region which plans and controls actions, solves problems and is involved in the working memory.
Life Sciences - Psychology
04.10.2016
Do Older People Take Fewer Risks?
Studies by the University of Basel have shown that whether and how risk-taking propensity varies over a person's life span depends in part on how risk taking is measured. When subjects are asked how they assess their risk propensity, a clear reduction with age is the result. However, this reduction is not necessarily observed for specific risk-taking tasks.
Medicine/Pharmacology - Life Sciences
04.10.2016
US FDA grants Breakthrough Therapy Designation for Roche’s Alecensa (alectinib) for first-line treatment of people with ALK-positive NSCLC
US FDA grants Breakthrough Therapy Designation for Roche's Alecensa (alectinib) for first-line treatment of people with ALK-positive NSCLC This second Alecensa Breakthrough Therapy Designation granted is based on phase 3 J-ALEX study Roche announced today that it has received a second Breakthrough Therapy Designation (BTD) from the United States Food and Drug Administration (FDA) for its ALK inhibitor, Alecensa (alectinib).
Physics/Materials Science
03.10.2016
Measuring forces with oscillations
Measuring forces with oscillations
Researchers at ETH Zurich have discovered a peculiar feature in oscillations similar to that of a child's swing. As a result, they have succeeded in outlining a novel principle for small, high-resolution sensors, and have submitted a patent application for it. A child swings on a swing, gaining momentum with its legs.
Medicine/Pharmacology
03.10.2016
Novartis reports over half of psoriasis patients do not reach the achievable treatment goal of clear skin in largest global survey
Global survey of over 8,300 patients shows over half have not achieved clear skin (57%), with the majority taking the historical standard of care treatment *   Majority (84%) face discrimination and
Medicine/Pharmacology - Life Sciences
03.10.2016
First phase III data on Roche’s TECENTRIQ (atezolizumab) to feature at the 2016 European Society for Medical Oncology (ESMO) Congress
First phase III data on Roche's TECENTRIQ (atezolizumab) to feature at the 2016 European Society for Medical Oncology (ESMO) Congress • Superiority results from the phase III OAK study comparing Tecentriq to chemotherapy in a difficult to treat type of lung cancer will be highlighted at the ESMO Presidential Symposium • Investigational cancer immunotherapy-based combination approaches across a range of cancer types to be showcased duri
Medicine/Pharmacology
01.10.2016
Novartis late-breaking data show Cosentyx delivers high and long-lasting skin clearance over 4 years for psoriasis patients
Cosentyx delivers long-lasting clear or almost clear skin (PASI 90 to PASI 100) in the vast majority of patients and continues to show a favorable safety profile over 4 years New data show that with Cosentyx almost 100% of PASI 90 and PASI 100 response rates are maintained from Year 1 to Year 4   Cosentyx significantly superior to Stelara in delivering long-lasting skin clearance in psoriasis over 52 weeks, confirms new JAAD publication The digi
Medicine/Pharmacology - Life Sciences
01.10.2016
Respiratory tract bacterium uncovered as trigger for serious nervous system disease
Respiratory tract bacterium uncovered as trigger for serious nervous system disease
The bacterium Mycoplasma pneumoniae has been under suspicion for quite a while. Now, researchers at the University of Zurich, the University Children's Hospital Zurich, and the Erasmus University in Rotterdam have proved without a doubt that it is the culprit. In fact, mycoplasma is not only responsible for respiratory tract infections such as pneumonia in children and adults, it can also trigger Guillain-Barré syndrome (GBS) in infected individuals.
Astronomy - Media
30.09.2016
Rosetta's momentous end
Rosetta’s momentous end
Rosetta's mission is over: After the last signal at 13:20, the spacecraft was crash-landed on comet Churyumov-Gerasimenko, with the ROSINA instrument from Bern taking measurements right until the very end.
Medicine/Pharmacology - Life Sciences
30.09.2016
Nine professors appointed at ETH Zurich
Nine professors appointed at ETH Zurich
Upon application of the President of ETH Zurich, Professor Lino Guzzella, at its meeting of 28/29 September 2016 the ETH Board appointed nine professors and took note of the resignation of 3 professors and thanked them for their services. Dr Rima Alaifari (*1987), currently a post-doctoral student at ETH Zurich, as Assistant Professor of Applied Mathematics.
Physics/Materials Science - Environment/Sustainable Development
30.09.2016
Rubidium pushes perovskite solar cells to 21.6% efficiency
Rubidium pushes perovskite solar cells to 21.6% efficiency
30.09.16 - EPFL scientists have stabilized perovskite solar cells by integrating rubidium into them.
Business/Economics - Politics
30.09.2016
Seven new professorships at the Department of Economics
The University of Zurich has proven that it can meet several US elite universities at eye level when it comes to recruiting the best talents.
Astronomy
29.09.2016
So long and thanks for the probes
For twelve years, the space probe Rosetta served mankind. The European Space Agency (ESA) mission is now drawing to a close as the probe reaches its final resting place on the target comet Tschuri on September 30, 2016.
Careers/Employment - Physics/Materials Science
28.09.2016
Nine EPFL scientists in Thomson Reuters Highly Cited Researchers
Nine EPFL scientists in Thomson Reuters Highly Cited Researchers
28.09.16 - Nine EPFL scientists have been included in the prestigious Thomson Reuters? list of Highly Cited Researchers.
Medicine/Pharmacology - Business/Economics
28.09.2016
Sandoz invites young entrepreneurs to enter Sandoz HACk, a global competition to help solve healthcare access challenges
Despite significant advances made by modern medicine, universal access to healthcare is still arguably the single largest unmet medical need   Sandoz "HACk" - Healthcare Access Challenge - is a compe
Medicine/Pharmacology - Physics/Materials Science
28.09.2016
Novartis announces Phase III study shows AMG 334 significantly reduces monthly migraine days in people with episodic migraine
ARISE, first pivotal Phase III study of AMG 334 (erenumab) in episodic migraine prevention, met primary endpoint, showing a statistically significant reduction in monthly migraine days vs placebo   People with episodic migraine experience up to 14 migraine days each month and lose a substantial part of their lives to this debilitating disease   AMG 334 is being co-developed by Novartis and Amgen Basel, September 28, 2016 - Novartis today announc
Social Sciences
28.09.2016
Breaking down the barriers in our minds
Breaking down the barriers in our minds
What role does technology play in equality for people with disabilities? Experts and scientists have been discussing this question in the run-up to the world's first Cybathlon at ETH Zurich.